Open Access
An overview of doxorubicin formulations in cancer therapy
Publication type: Journal Article
Publication date: 2014-01-01
scimago Q2
wos Q4
SJR: 0.468
CiteScore: 2.1
Impact factor: 1.3
ISSN: 09731482, 09741127, 19984138
PubMed ID:
25579518
Oncology
General Medicine
Radiology, Nuclear Medicine and imaging
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
16
18
20
|
|
|
International Journal of Molecular Sciences
19 publications, 3.15%
|
|
|
Pharmaceutics
15 publications, 2.48%
|
|
|
International Journal of Pharmaceutics
14 publications, 2.32%
|
|
|
Journal of Drug Delivery Science and Technology
11 publications, 1.82%
|
|
|
Frontiers in Pharmacology
10 publications, 1.66%
|
|
|
Biomedicine and Pharmacotherapy
9 publications, 1.49%
|
|
|
European Journal of Pharmaceutical Sciences
8 publications, 1.32%
|
|
|
Molecules
7 publications, 1.16%
|
|
|
Cancers
6 publications, 0.99%
|
|
|
Scientific Reports
6 publications, 0.99%
|
|
|
International Journal of Biological Macromolecules
6 publications, 0.99%
|
|
|
Molecular Medicine Reports
5 publications, 0.83%
|
|
|
Nanomaterials
5 publications, 0.83%
|
|
|
ACS Omega
5 publications, 0.83%
|
|
|
Nanomedicine
4 publications, 0.66%
|
|
|
Oncology Letters
4 publications, 0.66%
|
|
|
Pharmaceuticals
4 publications, 0.66%
|
|
|
Phytomedicine
4 publications, 0.66%
|
|
|
European Journal of Pharmacology
4 publications, 0.66%
|
|
|
Seminars in Cancer Biology
4 publications, 0.66%
|
|
|
Colloids and Surfaces B: Biointerfaces
4 publications, 0.66%
|
|
|
Translational Oncology
4 publications, 0.66%
|
|
|
Journal of Biochemical and Molecular Toxicology
4 publications, 0.66%
|
|
|
Current Cancer Therapy Reviews
3 publications, 0.5%
|
|
|
Aging
3 publications, 0.5%
|
|
|
Biomedicines
3 publications, 0.5%
|
|
|
Frontiers in Oncology
3 publications, 0.5%
|
|
|
Cancer Nanotechnology
3 publications, 0.5%
|
|
|
Pharmaceutical Research
3 publications, 0.5%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
Publishers
|
20
40
60
80
100
120
140
160
180
200
|
|
|
Elsevier
198 publications, 32.78%
|
|
|
MDPI
83 publications, 13.74%
|
|
|
Springer Nature
71 publications, 11.75%
|
|
|
Taylor & Francis
45 publications, 7.45%
|
|
|
Wiley
39 publications, 6.46%
|
|
|
American Chemical Society (ACS)
26 publications, 4.3%
|
|
|
Frontiers Media S.A.
25 publications, 4.14%
|
|
|
Royal Society of Chemistry (RSC)
18 publications, 2.98%
|
|
|
Spandidos Publications
12 publications, 1.99%
|
|
|
Bentham Science Publishers Ltd.
7 publications, 1.16%
|
|
|
SAGE
6 publications, 0.99%
|
|
|
Hindawi Limited
6 publications, 0.99%
|
|
|
Cold Spring Harbor Laboratory
5 publications, 0.83%
|
|
|
Impact Journals
3 publications, 0.5%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 0.5%
|
|
|
Baishideng Publishing Group
3 publications, 0.5%
|
|
|
IOP Publishing
3 publications, 0.5%
|
|
|
American Association for Cancer Research (AACR)
3 publications, 0.5%
|
|
|
World Scientific
2 publications, 0.33%
|
|
|
Neoplasia Press
2 publications, 0.33%
|
|
|
Georg Thieme Verlag KG
2 publications, 0.33%
|
|
|
Oxford University Press
2 publications, 0.33%
|
|
|
IntechOpen
2 publications, 0.33%
|
|
|
AME Publishing Company
2 publications, 0.33%
|
|
|
Mary Ann Liebert
2 publications, 0.33%
|
|
|
OAE Publishing Inc.
2 publications, 0.33%
|
|
|
International Heart Journal (Japanese Heart Journal)
1 publication, 0.17%
|
|
|
Beilstein-Institut
1 publication, 0.17%
|
|
|
Canadian Science Publishing
1 publication, 0.17%
|
|
|
20
40
60
80
100
120
140
160
180
200
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
604
Total citations:
604
Citations from 2024:
204
(33.77%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Rivankar S. An overview of doxorubicin formulations in cancer therapy // Journal of Cancer Research and Therapeutics. 2014. Vol. 10. No. 4. p. 853.
GOST all authors (up to 50)
Copy
Rivankar S. An overview of doxorubicin formulations in cancer therapy // Journal of Cancer Research and Therapeutics. 2014. Vol. 10. No. 4. p. 853.
Cite this
RIS
Copy
TY - JOUR
DO - 10.4103/0973-1482.139267
UR - https://doi.org/10.4103/0973-1482.139267
TI - An overview of doxorubicin formulations in cancer therapy
T2 - Journal of Cancer Research and Therapeutics
AU - Rivankar, S
PY - 2014
DA - 2014/01/01
PB - Ovid Technologies (Wolters Kluwer Health)
SP - 853
IS - 4
VL - 10
PMID - 25579518
SN - 0973-1482
SN - 0974-1127
SN - 1998-4138
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2014_Rivankar,
author = {S Rivankar},
title = {An overview of doxorubicin formulations in cancer therapy},
journal = {Journal of Cancer Research and Therapeutics},
year = {2014},
volume = {10},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
month = {jan},
url = {https://doi.org/10.4103/0973-1482.139267},
number = {4},
pages = {853},
doi = {10.4103/0973-1482.139267}
}
Cite this
MLA
Copy
Rivankar, S.. “An overview of doxorubicin formulations in cancer therapy.” Journal of Cancer Research and Therapeutics, vol. 10, no. 4, Jan. 2014, p. 853. https://doi.org/10.4103/0973-1482.139267.